Study of Energy Requirements in Critically Ill Newborns



Status:Recruiting
Conditions:Hospital, Pulmonary
Therapuetic Areas:Pulmonary / Respiratory Diseases, Other
Healthy:No
Age Range:Any
Updated:4/2/2016
Start Date:March 1997

Use our guide to learn which trials are right for you!

OBJECTIVES:

I. Determine the total energy expenditure in term and preterm infants in both well and ill
states using the doubly labeled water method.

PROTOCOL OUTLINE: Patients are assigned to one of three groups according to gestational age
(24-28 weeks estimated gestational age (EGA) vs 29-34 weeks EGA vs 35 weeks EGA and over)
and severity of respiratory illness (need for high frequency ventilation vs stable
conventional ventilator settings or extubated within past 24 hours vs no need for mechanical
ventilation).

Patients receive water labeled with deuterium and oxygen O 18 by mouth or by gastrostomy
tube on days 1 and 7. Urine samples are collected prior to the first dose, 4-6 hours after
the first dose, and then every 24 hours until the second dose. All urine is collected for
4-6 hours after the second dose. Samples are analyzed by dual inlet isotope ratio mass
spectrometry.

PROTOCOL ENTRY CRITERIA:

--Disease Characteristics--

Infants with estimated gestational age (EGA) of at least 24 weeks with respiratory illness
who are on high frequency ventilation (HFOV) and meet the following conditions:
Appropriate size for gestational age (AGA) No congenital anomalies No medical
complications, including seizures and necrotizing enterocolitis

OR

Control infants with EGA of at least 24 weeks Must meet 1 of the following conditions:
Requirement for stable conventional ventilator settings with respiratory index score of
less than 2.5 and/or extubated within past 24 hours No requirement for mechanical
ventilation Must meet all of the following conditions: AGA No congenital anomalies No
medical complications, including seizures and necrotizing enterocolitis No documented
sepsis by positive blood culture No supplemental oxygen use (infants 35 weeks EGA and over
only)

--Prior/Concurrent Therapy--

HFOV group: Concurrent surfactant, theophylline, or inotrope (vasopressor) therapy allowed

Control group: No concurrent inotrope (vasopressor) therapy
We found this trial at
1
site
425 University Blvd.
Indianapolis, Indiana 46202
(317) 274-4591
Indiana University INDIANA UNIVERSITY is a major multi-campus public research institution, grounded in the liberal...
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials